Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study to Evaluate the Efficacy of Quadrivalent HPV Vaccine in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related CIN, AIS, and Cervical Cancer, and HPV 6-, 11-, 16-, and 18-Related External Genital Warts, Vulvar Intraepithelial Neoplasia Vaginal Intraepithelial Neoplasia, Vulvar Cancer, and Vaginal Cancer in 16- to 23-Year-Old Women

Trial Profile

A Study to Evaluate the Efficacy of Quadrivalent HPV Vaccine in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related CIN, AIS, and Cervical Cancer, and HPV 6-, 11-, 16-, and 18-Related External Genital Warts, Vulvar Intraepithelial Neoplasia Vaginal Intraepithelial Neoplasia, Vulvar Cancer, and Vaginal Cancer in 16- to 23-Year-Old Women

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary) ; Hepatitis B vaccine recombinant; Human papillomavirus vaccine
  • Indications Adenocarcinoma; Cervical cancer; Cervical intraepithelial neoplasia; Genital warts; Hepatitis B; Human papillomavirus infections; Vaginal intraepithelial neoplasia; Vulvar intraepithelial neoplasia
  • Focus Registrational; Therapeutic Use
  • Acronyms FUTURE-I
  • Sponsors Merck & Co; Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
  • Most Recent Events

    • 20 Jul 2010 Results of a pooled analysis of the FUTURE-I and -II trials have been published in the British Medical Journal.
    • 17 Dec 2009 Actual number of patients changed from 5700 to 5759 as reported by ClinicalTrials.gov NCT00092521.
    • 14 Jul 2009 Actual number of patients changed from 5455 to 5700 as reported by ClinicalTrials.gov NCT00092521.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top